387 related articles for article (PubMed ID: 18201278)
21. Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET.
Brest P; Gustafsson M; Mossberg AK; Gustafsson L; Duringer C; Hamiche A; Svanborg C
Cancer Res; 2007 Dec; 67(23):11327-34. PubMed ID: 18056459
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors preferentially augment transient transgene expression in human dermal fibroblasts.
Yasukawa K; Sawamura D; Goto M; Nakamura H; Shimizu H
Br J Dermatol; 2007 Oct; 157(4):662-9. PubMed ID: 17711521
[TBL] [Abstract][Full Text] [Related]
23. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
Thomas S; Munster PN
Cancer Lett; 2009 Aug; 280(2):184-91. PubMed ID: 19185986
[TBL] [Abstract][Full Text] [Related]
25. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis.
Chen J; Du C; Kang J; Wang J
Chem Biol Interact; 2008 Jan; 171(1):26-36. PubMed ID: 17961528
[TBL] [Abstract][Full Text] [Related]
26. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
[TBL] [Abstract][Full Text] [Related]
27. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
Savickiene J; Treigyte G; Magnusson KE; Navakauskiene R
Ann N Y Acad Sci; 2009 Aug; 1171():321-33. PubMed ID: 19723072
[TBL] [Abstract][Full Text] [Related]
28. Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells.
Chen J; Bai H; Wang C; Kang J
Pharmazie; 2006 Aug; 61(8):710-6. PubMed ID: 16964716
[TBL] [Abstract][Full Text] [Related]
29. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Poli R; Bosco O; Mastrocola R; Aragno M; Boccuzzi G
J Endocrinol; 2006 Nov; 191(2):465-72. PubMed ID: 17088416
[TBL] [Abstract][Full Text] [Related]
30. Synergistic killing of human leukemia cells by antioxidants and trichostatin A.
Kang J; Chen J; Zhang D; Da W; Ou Y
Cancer Chemother Pharmacol; 2004 Dec; 54(6):537-45. PubMed ID: 15248029
[TBL] [Abstract][Full Text] [Related]
31. Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments.
Karagiannis TC; Harikrishnan KN; El-Osta A
Oncogene; 2007 Jun; 26(27):3963-71. PubMed ID: 17213813
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors: molecular mechanisms of action.
Xu WS; Parmigiani RB; Marks PA
Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
[TBL] [Abstract][Full Text] [Related]
33. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
34. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
Rahim R; Strobl JS
Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707
[TBL] [Abstract][Full Text] [Related]
35. Sensitization of tumor cells by targeting histone deacetylases.
Perego P; Zuco V; Gatti L; Zunino F
Biochem Pharmacol; 2012 Apr; 83(8):987-94. PubMed ID: 22120677
[TBL] [Abstract][Full Text] [Related]
36. Effect of the histone deacetylase inhibitor trichostatin a in human peripheral blood lymphocytes as a function of donor age.
Sourlingas TG; Kypreou KP; Topakas GN; Karchilaki IN; Stavropoulos-Giokas C; Sekeri-Pataryas KE
Ann N Y Acad Sci; 2007 Nov; 1119():64-71. PubMed ID: 18056955
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
38. Antioxidants and trichostatin A synergistically protect against in vitro cytotoxicity of Ni2+ in human hepatoma cells.
Kang J; Zhang D; Chen J; Liu Q; Lin C
Toxicol In Vitro; 2005 Mar; 19(2):173-82. PubMed ID: 15649630
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.
Sasaki K; Yamagata T; Mitani K
Cancer Sci; 2008 Feb; 99(2):414-22. PubMed ID: 18271940
[TBL] [Abstract][Full Text] [Related]
40. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]